Amancio Carnero

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9267837/publications.pdf

Version: 2024-02-01

187 papers	9,860 citations	46918 47 h-index	43802 91 g-index
192 all docs	192 docs citations	192 times ranked	15497 citing authors

#	Article	IF	Citations
1	SPINOPHILIN: A multiplayer tumor suppressor. Genes and Diseases, 2023, 10, 187-198.	1.5	1
2	3D and organoid culture in research: physiology, hereditary genetic diseases and cancer. Cell and Bioscience, 2022, 12, 39.	2.1	23
3	Senotherapeutics in Cancer and HIV. Cells, 2022, 11, 1222.	1.8	7
4	A Six-Gene Prognostic and Predictive Radiotherapy-Based Signature for Early and Locally Advanced Stages in Non-Small-Cell Lung Cancer. Cancers, 2022, 14, 2054.	1.7	4
5	Molecular Radiobiology in Non-Small Cell Lung Cancer: Prognostic and Predictive Response Factors. Cancers, 2022, 14, 2202.	1.7	3
6	Editor's Note: Immortalization of Primary Human Prostate Epithelial Cells by c-Myc. Cancer Research, 2022, 82, 2656-2656.	0.4	0
7	Mutation of SPINOPHILIN (PPP1R9B) found in human tumors promotes the tumorigenic and stemness properties of cells. Theranostics, 2021, 11, 3452-3471.	4.6	3
8	NAD+ metabolism, stemness, the immune response, and cancer. Signal Transduction and Targeted Therapy, 2021, 6, 2.	7.1	189
9	Role of the Holoenzyme PP1-SPN in the Dephosphorylation of the RB Family of Tumor Suppressors During Cell Cycle. Cancers, 2021, 13, 2226.	1.7	5
10	Regulation of sarcomagenesis by the empty spiracles homeobox genes EMX1 and EMX2. Cell Death and Disease, 2021, 12, 515.	2.7	10
11	Cellular senescence or stemness: hypoxia flips the coin. Journal of Experimental and Clinical Cancer Research, 2021, 40, 243.	3.5	22
12	Empty spiracles homeobox genes EMX1 and EMX2 regulate WNT pathway activation in sarcomagenesis. Journal of Experimental and Clinical Cancer Research, 2021, 40, 247.	3.5	6
13	Leveraging Genomics, Transcriptomics, and Epigenomics to Understand the Biology and Chemoresistance of Ovarian Cancer. Cancers, 2021, 13, 4029.	1.7	10
14	Role of Mitochondria in Cancer Stem Cell Resistance. Cells, 2020, 9, 1693.	1.8	59
15	Breast tumor cells promotes the horizontal propagation of EMT, stemness, and metastasis by transferring the MAP17 protein between subsets of neoplastic cells. Oncogenesis, 2020, 9, 96.	2.1	12
16	Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment. Signal Transduction and Targeted Therapy, 2020, 5, 195.	7.1	8
17	Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness. Frontiers in Oncology, 2020, 10, 1533.	1.3	27
18	Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer. Cells, 2020, 9, 1402.	1.8	46

#	Article	IF	Citations
19	FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. EBioMedicine, 2020, 53, 102683.	2.7	15
20	Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness. Molecular Cancer, 2020, 19, 7.	7.9	72
21	The Tumor Suppressor Roles of MYBBP1A, a Major Contributor to Metabolism Plasticity and Stemness. Cancers, 2020, 12, 254.	1.7	20
22	PAI1 is a Marker of Bad Prognosis in Rectal Cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208. Cells, 2020, 9, 1071.	1.8	7
23	Combined MEK and PI3K/p110Î² Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. Cancer Research, 2020, 80, 843-856.	0.4	19
24	Tumor Profiling at the Service of Cancer Therapy. Frontiers in Oncology, 2020, 10, 595613.	1.3	9
25	Implications of maraviroc and/or rapamycin in a mouse model of fragility. Aging, 2020, 12, 8565-8582.	1.4	5
26	Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry. Cells, 2019, 8, 806.	1.8	3
27	New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools. Journal of Experimental and Clinical Cancer Research, 2019, 38, 234.	3.5	25
28	câ€MYBâ€and PGC1aâ€dependent metabolic switch induced by MYBBP1A loss in renal cancer. Molecular Oncology, 2019, 13, 1519-1533.	2.1	15
29	NAMPT as a Dedifferentiation-Inducer Gene: NAD+ as Core Axis for Glioma Cancer Stem-Like Cells Maintenance. Frontiers in Oncology, 2019, 9, 292.	1.3	31
30	FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy. Journal of Thoracic Oncology, 2019, 14, 641-655.	0.5	50
31	FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effective. Lung Cancer, 2019, 131, 112-121.	0.9	12
32	Loss of MYBBP1A Induces Cancer Stem Cell Activity in Renal Cancer. Cancers, 2019, 11, 235.	1.7	12
33	Tumor cell-secreted PLD increases tumor stemness by senescence-mediated communication with microenvironment. Oncogene, 2019, 38, 1309-1323.	2.6	34
34	The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction. Scientific Reports, 2018, 8, 2394.	1.6	26
35	MAP17 (PDZK1IP1) and pH2AX are potential predictive biomarkers for rectal cancer treatment efficacy. Oncotarget, 2018, 9, 32958-32971.	0.8	15
36	Synthesis, Reactivity Studies, and Cytotoxicity of Two trans-Iodidoplatinum(II) Complexes. Does Photoactivation Work?. Inorganics, 2018, 6, 127.	1.2	4

#	Article	IF	Citations
37	Dr. Jekyll and Mr. Hyde: MAP17â€™s up-regulation, a crosspoint in cancer and inflammatory diseases. Molecular Cancer, 2018, 17, 80.	7.9	14
38	MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 195.	3.5	20
39	NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP. Clinical Cancer Research, 2018, 24, 1202-1215.	3.2	106
40	Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer. Oncotarget, 2018, 9, 4395-4410.	0.8	37
41	NUMB and NUMBL differences in gene regulation. Oncotarget, 2018, 9, 9219-9234.	0.8	11
42	Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer. Oncotarget, 2018, 9, 19945-19960.	0.8	6
43	The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB. Clinical Cancer Research, 2017, 23, 3871-3883.	3.2	53
44	Prognostic relevance of Src activation in stage II-III colon cancer. Human Pathology, 2017, 67, 119-125.	1.1	15
45	Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Annals of Oncology, 2017, 28, 2994-2999.	0.6	45
46	Genome-Wide miRNA Screening for Genes Bypassing Oncogene-Induced Senescence. Methods in Molecular Biology, 2017, 1534, 53-68.	0.4	1
47	NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis. Oncotarget, 2017, 8, 99514-99530.	0.8	67
48	The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment. Oncotarget, 2017, 8, 98580-98597.	0.8	19
49	Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus. Oncotarget, 2017, 8, 58872-58886.	0.8	24
50	Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer. Oncotarget, 2017, 8, 105196-105210.	0.8	14
51	Numb-like (NumbL) downregulation increases tumorigenicity, cancer stem cell-like properties and resistance to chemotherapy. Oncotarget, 2016, 7, 63611-63628.	0.8	36
52	Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. Oncotarget, 2016, 7, 33111-33124.	0.8	27
53	The cancer stem-cell signaling network and resistance to therapy. Cancer Treatment Reviews, 2016, 49, 25-36.	3.4	122
54	The role of PIM1/PIM2 kinases in tumors of the male reproductive system. Scientific Reports, 2016, 6, 38079.	1.6	28

#	Article	IF	Citations
55	The hypoxic microenvironment: A determinant of cancer stem cell evolution. BioEssays, 2016, 38, S65-74.	1.2	164
56	Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy. BMC Cancer, 2016, 16, 829.	1.1	1
57	The Cytoskeletal Adapter Protein Spinophilin Regulates Invadopodia Dynamics and Tumor Cell Invasion in Glioblastoma. Molecular Cancer Research, 2016, 14, 1277-1287.	1.5	20
58	The hypoxic microenvironment: A determinant of cancer stem cell evolution. Inside the Cell, 2016, 1, 96-105.	0.4	7
59	IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF). Journal of Thoracic Oncology, 2016, 11, 2183-2192.	0.5	19
60	A genetic view of laryngeal cancer heterogeneity. Cell Cycle, 2016, 15, 1202-1212.	1.3	27
61	Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors. Oncogene, 2016, 35, 2777-2788.	2.6	31
62	Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1). Oncotarget, 2016, 7, 67033-67046.	0.8	23
63	Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival. Oncotarget, 2016, 7, 31723-31737.	0.8	15
64	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis, 2015, 36, S254-S296.	1.3	239
65	Senescence in Oncogenesis: From Molecular Mechanisms to Therapeutic Opportunities. , 2015, , 127-155.		0
66	Disruptive chemicals, senescence and immortality. Carcinogenesis, 2015, 36, S19-S37.	1.3	32
67	Therapeutic targeting of replicative immortality. Seminars in Cancer Biology, 2015, 35, S104-S128.	4.3	49
68	MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFÎºB Activation in Breast Cancer. Molecular Cancer Therapeutics, 2015, 14, 1454-1465.	1.9	26
69	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	4.3	220
70	Genetic modification of hypoxia signaling in animal models and its effect on cancer. Clinical and Translational Oncology, 2015, 17, 90-102.	1.2	11
71	Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. Oncotarget, 2015, 6, 6151-6159.	0.8	28
72	MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer. Oncotarget, 2015, 6, 12625-12636.	0.8	26

#	Article	IF	Citations
73	High casein kinase 1 epsilon levels are correlated with better prognosis in subsets of patients with breast cancer. Oncotarget, 2015, 6, 30343-30356.	0.8	6
74	Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. Oncotarget, 2015, 6, 40557-40574.	0.8	53
75	Decoding Warburg's hypothesis: tumor-related mutations in the mitochondrial respiratory chain. Oncotarget, 2015, 6, 41582-41599.	0.8	44
76	MAP17 as Biomarker for Cancer Treatment. Biomarkers in Disease, 2015, , 167-178.	0.0	0
77	Prognostic relevance of estrogen receptor-Î± Ser167 phosphorylation in stage II-III colon cancer patients. Human Pathology, 2014, 45, 2437-2446.	1.1	13
78	MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer, 2014, 14, 656.	1.1	64
79	The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. Frontiers in Oncology, 2014, 4, 252.	1.3	166
80	Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis. BMC Cancer, 2014, 14, 281.	1.1	11
81	MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD. European Respiratory Journal, 2014, 43, 1740-1749.	3.1	91
82	The PIM Family of Serine/Threonine Kinases in Cancer. Medicinal Research Reviews, 2014, 34, 136-159.	5.0	191
83	MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e90524.	1.1	65
84	MAP17 as Biomarker for Cancer Treatment. , 2014, , 1-10.		0
85	Identification of proteomic signatures associated with lung cancer and COPD. Journal of Proteomics, 2013, 89, 227-237.	1.2	116
86	Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncology, The, 2013, 14, e358-e369.	5.1	313
87	Proteomic biomarkers in lung cancer. Clinical and Translational Oncology, 2013, 15, 671-682.	1.2	29
88	The second generation of iodido complexes: trans-[PtI2(amine)(amineâ€²)] bearing different aliphatic amines. Journal of Inorganic Biochemistry, 2013, 127, 182-187.	1.5	15
89	Markers of Cellular Senescence. Methods in Molecular Biology, 2013, 965, 63-81.	0.4	62
90	Oxidation of anticancer Pt(ii) complexes with monodentate phosphane ligands: towards stable but active Pt(iv) prodrugs. Chemical Communications, 2013, 49, 4806.	2.2	21

#	Article	IF	Citations
91	Pim kinases in cancer: Diagnostic, prognostic and treatment opportunities. Biochemical Pharmacology, 2013, 85, 629-643.	2.0	137
92	DNA Methylation Signatures Identify Biologically Distinct Thyroid Cancer Subtypes. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2811-2821.	1.8	100
93	Identification of Oxidative Stress Related Proteins as Biomarkers for Lung Cancer and Chronic Obstructive Pulmonary Disease in Bronchoalveolar Lavage. International Journal of Molecular Sciences, 2013, 14, 3440-3455.	1.8	33
94	Spinophilin Loss Correlates with Poor Patient Prognosis in Advanced Stages of Colon Carcinoma. Clinical Cancer Research, 2013, 19, 3925-3935.	3.2	16
95	Conditional Transgenic Expression of PIM1 Kinase in Prostate Induces Inflammation-Dependent Neoplasia. PLoS ONE, 2013, 8, e60277.	1.1	28
96	MAP17 and SGLT1 Protein Expression Levels as Prognostic Markers for Cervical Tumor Patient Survival. PLoS ONE, 2013, 8, e56169.	1.1	45
97	p38Î± limits the contribution of MAP17 to cancer progression in breast tumors. Oncogene, 2012, 31, 4447-4459.	2.6	26
98	MAP17, a ROS-dependent oncogene. Frontiers in Oncology, 2012, 2, 112.	1.3	15
99	The essential role of PIM kinases in sarcoma growth and bone invasion. Carcinogenesis, 2012, 33, 1479-1486.	1.3	34
100	PDGFRÎ±/Î² and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome. BMC Cancer, 2012, 12, 514.	1.1	14
101	Association between the miRNA Signatures in Plasma and Bronchoalveolar Fluid in Respiratory Pathologies. Disease Markers, 2012, 32, 221-230.	0.6	37
102	MAP17 and the double-edged sword of ROS. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 44-52.	3.3	22
103	Spinophilin: A New Tumor Suppressor at 17q21. Current Molecular Medicine, 2012, 12, 528-535.	0.6	19
104	Association between the miRNA signatures in plasma and bronchoalveolar fluid in respiratory pathologies. Disease Markers, 2012, 32, 221-30.	0.6	27
105	The preparation and characterization of trans-platinum(iv) complexes with unusually high cytotoxicity. Dalton Transactions, 2011, 40, 344-347.	1.6	29
106	Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition. Cancer Letters, 2011, 300, 145-153.	3.2	53
107	Cancer, Senescence, and Aging: Translation from Basic Research to Clinics. Journal of Aging Research, 2011, 2011, 1-2.	0.4	1
108	Epigenetic mechanisms in senescence, immortalisation and cancer. Biological Reviews, 2011, 86, 443-455.	4.7	17

#	Article	IF	Citations
109	Downâ€regulation of spinophilin in lung tumours contributes to tumourigenesis. Journal of Pathology, 2011, 225, 73-82.	2.1	20
110	Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. Cell Cycle, 2011, 10, 2751-2762.	1.3	40
111	Cellular Senescence as a Target in Cancer Control. Journal of Aging Research, 2011, 2011, 1-12.	0.4	32
112	Spinophilin loss contributes to tumorigenesis in vivo. Cell Cycle, 2011, 10, 1948-1955.	1.3	31
113	Bypassing cellular senescence by genetic screening tools. Clinical and Translational Oncology, 2010, 12, 410-417.	1.2	26
114	The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine. European Journal of Medicinal Chemistry, 2010, 45, 134-141.	2.6	22
115	Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells. Oncogene, 2010, 29, 2973-2982.	2.6	85
116	Exploring the Gain of Function Contribution of AKT to Mammary Tumorigenesis in Mouse Models. PLoS ONE, 2010, 5, e9305.	1.1	28
117	The TGF-Î² co-receptor endoglin modulates the expression and transforming potential of H-Ras. Carcinogenesis, 2010, 31, 2145-2154.	1.3	23
118	Targeting of p53-Transcriptional Dysfunction by Conditionally Replicating Adenovirus Is Not Limited by p53-Homologues. Molecular Therapy, 2010, 18, 936-946.	3.7	7
119	The PKB/AKT Pathway in Cancer. Current Pharmaceutical Design, 2010, 16, 34-44.	0.9	252
120	Understanding FOXO, New Views on Old Transcription Factors. Current Cancer Drug Targets, 2010, 10, 135-146.	0.8	52
121	Between Bench and Bed Side: PI3K Inhibitors. Current Molecular Pharmacology, 2010, 3, 79-90.	0.7	1
122	Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases. Journal of Biological Chemistry, 2009, 284, 28392-28400.	1.6	77
123	Cold-Inducible RNA-Binding Protein Bypasses Replicative Senescence in Primary Cells through Extracellular Signal-Regulated Kinase 1 and 2 Activation. Molecular and Cellular Biology, 2009, 29, 1855-1868.	1.1	69
124	Using cells devoid of RAS proteins as tools for drug discovery. Molecular Carcinogenesis, 2009, 48, 1038-1047.	1.3	7
125	Inhibiting PI3K as a therapeutic strategy against cancer. Clinical and Translational Oncology, 2009, 11, 572-579.	1.2	28
126	Adding more content to screening: reactivation of FOXO as a therapeutic strategy. Clinical and Translational Oncology, 2009, 11, 651-658.	1.2	6

#	Article	IF	Citations
127	Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators. BMC Cell Biology, 2009, 10, 14.	3.0	41
128	Novel inhibitors of the PI3K family. Expert Opinion on Investigational Drugs, 2009, 18, 1265-1277.	1.9	36
129	Influence of amine ligands on the aquation and cytotoxicity of trans-diamine platinum(ii) anticancer complexes. Dalton Transactions, 2009, , 3457.	1.6	41
130	Mouse Models to Decipher the PI3K Signaling Network in Human Cancer. Current Molecular Medicine, 2009, 9, 612-625.	0.6	19
131	Genetic modelling of the PTEN/AKT pathway in cancer research. Clinical and Translational Oncology, 2008, 10, 618-627.	1.2	19
132	Chemical Genetic Analysis of FOXO Nuclearâ€“Cytoplasmic Shuttling by Using Imageâ€Based Cell Screening. ChemBioChem, 2008, 9, 2229-2237.	1.3	79
133	Isolation of an Intermediate in the Platination ofp-Nitroacetophenone 4-Methylthiosemicarbazone: Potential Application as an Antitumor Drug. European Journal of Inorganic Chemistry, 2008, 2008, 1183-1187.	1.0	17
134	Platinum(IV) Complexes of 3- and 4-Picolinic Acids Containing Ammine or Isopropylamine Ligands - Synthesis, CharacteriÂzation, X-ray Structures, and Evaluation of Their Cytotoxic Activity against Cancer Cell Lines. European Journal of Inorganic Chemistry, 2008, 2008, 4762-4769.	1.0	8
135	Influence of (Hydroxymethyl)pyridine and Pyridineâ€carboxylic Acids, in transâ€Position to the Isopropylamine and Ammine Ligands, on the Cytotoxicity of Platinum Complexes. Chemistry and Biodiversity, 2008, 5, 2090-2100.	1.0	11
136	Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene, 2008, 27, 1961-1970.	2.6	59
137	S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis. Carcinogenesis, 2008, 29, 2089-2095.	1.3	65
138	Activation of Phosphatidylinositol 3-Kinase by Membrane Localization of p110Î± Predisposes Mammary Glands to Neoplastic Transformation. Cancer Research, 2008, 68, 9643-9653.	0.4	47
139	Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function. Carcinogenesis, 2008, 29, 1343-1350.	1.3	24
140	Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines. Molecular Cancer Therapeutics, 2008, 7, 2358-2366.	1.9	25
141	The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications. Current Cancer Drug Targets, 2008, 8, 187-198.	0.8	685
142	A Dual-Color Fluorescence-Based Platform to Identify Selective Inhibitors of Akt Signaling. PLoS ONE, 2008, 3, e1823.	1.1	17
143	Characterization of the p53 Response to Oncogene-Induced Senescence. PLoS ONE, 2008, 3, e3230.	1.1	41
144	An HTS Approach to Screen for Antagonists of the Nuclear Export Machinery Using High Content Cell-Based Assays. Assay and Drug Development Technologies, 2007, 5, 333-342.	0.6	45

#	Article	IF	Citations
145	MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis, 2007, 28, 1646-1652.	1.3	48
146	PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis, 2007, 29, 491-499.	1.3	61
147	MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation. Carcinogenesis, 2007, 28, 2443-2450.	1.3	30
148	MAP17 enhances the malignant behavior of tumor cells through ROS increase. Carcinogenesis, 2007, 28, 2096-2104.	1.3	55
149	Levels of p27kip1 determine Aplidin sensitivity. Molecular Cancer Therapeutics, 2007, 6, 1310-1316.	1.9	31
150	Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis, 2007, 28, 584-594.	1.3	44
151	Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate. Carcinogenesis, 2007, 28, 1418-1425.	1.3	25
152	Cellular Senescence as a Target in Cancer Control. Current Cancer Therapy Reviews, 2007, 3, 7-15.	0.2	4
153	Expression of CYP3A4 as a predictor of response to chemotherapy in peripheral T-cell lymphomas. Blood, 2007, 110, 3345-3351.	0.6	42
154	PTEN, more than the AKT pathway. Carcinogenesis, 2007, 28, 1379-1386.	1.3	355
155	Newtrans-Platinum Drugs with Phosphines and Amines as Carrier Ligands Induce Apoptosis in Tumor Cells Resistant to Cisplatin. Journal of Medicinal Chemistry, 2007, 50, 2194-2199.	2.9	61
156	Extreme sensitivity to YondelisÂ® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. Journal of Cellular Biochemistry, 2007, 100, 339-348.	1.2	39
157	Structureâ€“activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death. Journal of Inorganic Biochemistry, 2007, 101, 551-558.	1.5	12
158	High throughput screening in drug discovery. Clinical and Translational Oncology, 2006, 8, 482-490.	1.2	98
159	Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria. Anti-Cancer Drugs, 2005, 16, 977-987.	0.7	20
160	CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus. Oncogene, 2005, 24, 5543-5551.	2.6	147
161	Identification of transcripts specific for physiological gene activation by platelet-derived growth factor (PDGF)-B in intact brain tissue. Journal of Cellular Biochemistry, 2005, 95, 859-867.	1.2	1
162	Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. Journal of Cellular Biochemistry, 2005, 95, 979-989.	1.2	35

#	Article	IF	Citations
163	Roscovitine Targets, Protein Kinases and Pyridoxal Kinase. Journal of Biological Chemistry, 2005, 280, 31208-31219.	1.6	312
164	Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naÃ¯ve patients. Molecular Cancer Therapeutics, 2005, 4, 814-823.	1.9	50
165	Immortalization of Primary Human Prostate Epithelial Cells by c-Myc. Cancer Research, 2005, 65, 2179-2185.	0.4	112
166	Cooperation between Cdk4 and p27kip1 in Tumor Development: A Preclinical Model to Evaluate Cell Cycle Inhibitors with Therapeutic Activity. Cancer Research, 2005, 65, 3846-3852.	0.4	55
167	EMX homeobox genes regulate microphthalmia and alter melanocyte biology. Experimental Cell Research, 2005, 311, 27-38.	1.2	14
168	Glycolytic enzymes can modulate cellular life span. Cancer Research, 2005, 65, 177-85.	0.4	458
169	Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation. Oncogene, 2004, 23, 6006-6011.	2.6	37
170	Cellular senescence induced by p53-ras cooperation is independent of p21waf1 in murine embryo fibroblasts. Journal of Cellular Biochemistry, 2004, 92, 514-524.	1.2	19
171	Non-neutral role of replicative senescence in tissue homeostasis and tumorigenesis. Journal of Theoretical Biology, 2004, 230, 333-341.	0.8	6
172	Overexpression of cyclin D1 inhibits TNF-induced growth arrest. Journal of Cellular Biochemistry, 2003, 89, 484-499.	1.2	12
173	Exploring cellular senescence as a tumor suppressor mechanism. , 2003, 5, 249-265.		3
174	Cell cycle deregulation: a common motif in cancer. Progress in Cell Cycle Research, 2003, 5, 5-18.	0.9	62
175	p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nature Cell Biology, 2000, 2, 148-155.	4.6	266
176	Cell cycle and cancer. , 2000, 2, 12-22.		3
177	MOLECULAR GENETICS:MaRX: An Approach to Genetics in Mammalian Cells. Science, 1999, 283, 1129-1130.	6.0	92
178	A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity. Journal of Experimental Medicine, 1999, 190, 1375-1382.	4.2	564
179	Wortmannin, an inhibitor of phosphatidyl-inositol 3-kinase, induces oocyte maturation through a MPF-MAPK-dependent pathway. FEBS Letters, 1998, 422, 155-159.	1.3	18
180	Rho proteins induce metastatic properties in vivo. Oncogene, 1997, 15, 3047-3057.	2.6	153

#	Article	IF	Citations
181	Modulation of cellular chemoresistance in keratinocytes by activation of different oncogenes. International Journal of Cancer, 1995, 60, 235-243.	2.3	26
182	ras-p21 Activates phospholipase D and A2, but not phospholipase C or PKC, inXenopus laevis Oocytes. Journal of Cellular Biochemistry, 1994, 54, 478-486.	1.2	33
183	Progesterone but notras requires MPF for in vivo activation of MAPK and S6 KII: MAPK is an essential conexion point of both signaling pathways. Journal of Cellular Biochemistry, 1994, 55, 465-476.	1.2	19
184	Phospholipase-induced maturation ofXenopus laevis oocytes: Mitogenic activity of generated metabolites. Journal of Cellular Biochemistry, 1993, 52, 440-448.	1.2	30
185	Acylphosphatase synergizes with progesterone during maturation ofXenopus laevisoocytes. FEBS Letters, 1993, 327, 265-270.	1.3	6
186	Microinjection of acylphosphatase blocksXenopus laevisoocytes maturation induced byras-p21. FEBS Letters, 1993, 326, 167-170.	1.3	7
187	PI3K pathway in cancer. , 0, , 193-203.		0